AAArnaud Agin

Arnaud Agin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arnaud Agin has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Françoise Gasser

    Laboratoire d’Hormonologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

    2 shared publications
  • Rémy Sapin

    Laboratoire d’Hormonologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

    2 shared publications
  • Benjamin Cretin

    ICube laboratory, UMR 7357, team IMIS and platform IRIS, University of Strasbourg, CNRS, FMTS (Fédération de Médicine Translationnelle de Strasbourg, Strasbourg, France

    1 shared publication
  • Béatrice Heurtault

    Laboratoire d’Hormonologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

    1 shared publication
  • Catherine Demuynck

    Geriatrics Department, CM2R (Memory Resource and Research Centre), Day Hospital & Neurology Service, Neuropsychology Unit, University Hospital of Strasbourg, Strasbourg, France

    1 shared publication
  • Catherine Martin-Hunyadi

    Geriatrics Department, CM2R (Memory Resource and Research Centre), Day Hospital & Neurology Service, Neuropsychology Unit, University Hospital of Strasbourg, Strasbourg, France

    1 shared publication

Latest Publications

  • Environmental exposure to phthalates and dementia with Lewy bodies: contribution of metabolomics

    by Arnaud Agin, Frédéric Blanc, Olivier Bousiges, Claire Villette, Nathalie Philippi, Catherine Demuynck, Catherine Martin-Hunyadi, Benjamin Cretin, Sabine Lang, Julie Zumsteg, et al.

    Background In neurodegenerative diseases, alongside genetic factors, the possible intervention of environmental factors in the pathogenesis is increasingly being considered. In particular, recent evidence suggests the intervention of a pesticide-like xenobiotic in the initiation of disease with Lewy bodies (DLB). Objectives To test for the presence of pesticides or other xenobiotics in the cerebrospinal fluid (CSF) of patients with DLB. Methods A total of 45 patients were included in this study: 16 patients with DLB at the prodromal stage, 8 patients with DLB at the demented stage, 8 patients with Alzheimer’s disease (AD) at the prodromal stage and 13 patients with AD at the demented stage. CSF was obtained by lumbar puncture and analysed by liquid chromatography–mass spectrometry. Results Among the compounds detected in greater abundance in the CSF of patients with DLB compared with patients with AD, only one had a xenobiotic profile potentially related to the pathophysiology of DLB. After normalisation and scaling, bis(2-ethylhexyl) phthalate was more abundant in the CSF of patients with DLB (whole cohort: 2.7-fold abundant in DLB, p=0.031; patients with dementia: 3.8-fold abundant in DLB, p=0.001). Conclusions This study is the first reported presence of a phthalate in the CSF of patients with DLB. This molecule, which is widely distributed in the environment and enters the body orally, nasally and transdermally, was first introduced in the 1920s as a plasticizer. Thereafter, the first cases of DLB were described in the 1960s and 1970s. These observations suggest that phthalates may be involved in the pathophysiology of DLB.


  • Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification

    by Béatrice Heurtault, Nathalie Reix, Nicolas Meyer, Françoise Gasser, Marie-Josée Wendling, Charline Ratomponirina, Nathalie Jeandidier, Rémy Sapin, Arnaud Agin

    Background: Over the last few decades, new synthetic insulin analogues have been developed. Their measurement is of prime importance in the investigation of hypoglycaemia, but their quantification is hampered by variable cross-reactivity with many insulin assays. For clinical analysis, it has now become essential to know the potential cross-reactivity of analogues of interest. Methods: In this work, we performed an extensive study of insulin analogue cross-reactivity using numerous human insulin immunoassays. We investigated the cross-reactivity of five analogues (lispro, aspart, glulisine, glargine, detemir) and two glargine metabolites (M1 and M2) with 16 commercial human insulin immunoassays as a function of concentration. Results: The cross-reactivity values for insulin analogues or glargine metabolites ranged from 0% to 264%. Four assays were more specific to human insulin, resulting in negligible cross-reactivity with the analogues. However, none of the 16 assays was completely free of cross-reactivity with analogues or metabolites. The results show that analogue cross-reactivity, which varies to a large degree, is far from negligible, and should not be overlooked in clinical investigations. Conclusions: This study has established the cross-reactivity of five insulin analogues and two glargine metabolites using 16 immunoassays to facilitate the choice of the immunoassay(s) and to provide sensitive and specific analyses in clinical routine or investigation.


  • Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment

    by Arnaud Agin, Nathalie Jeandidier, Françoise Gasser, Daniel Grucker, Rémy Sapin

    Clin Chem Lab Med 2006;44:1379–82.